Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532

Phase 1 Completed 27 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The primary purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of a single oral dose of PF-04991532 in subjects with renal impairment.

Timeline

Start: 2011-07
Primary completion: 2012-02
Completion: 2012-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-04991532	Small molecule	300 mg	Oral

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532

Summary

Timeline

Drugs

Indications